PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32276399-5 2020 In addition, the IFNL4 genotype was the primary polymorphism responsible for a suboptimal treatment response to pegylated IFN-alpha and ribavirin. Ribavirin 136-145 interferon lambda 4 (gene/pseudogene) Homo sapiens 17-22 33127459-0 2020 Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin. Ribavirin 141-150 interferon lambda 4 (gene/pseudogene) Homo sapiens 0-19 33127459-2 2020 So, a single nucleotide polymorphisms (SNP) of IFNL4 gene genotypes and its relationship with Sofosbuvir (SOF) and Ribavirin (RBV) treatment response is under consideration. Ribavirin 115-124 interferon lambda 4 (gene/pseudogene) Homo sapiens 47-52 33127459-2 2020 So, a single nucleotide polymorphisms (SNP) of IFNL4 gene genotypes and its relationship with Sofosbuvir (SOF) and Ribavirin (RBV) treatment response is under consideration. Ribavirin 126-129 interferon lambda 4 (gene/pseudogene) Homo sapiens 47-52 30027841-1 2019 Genetic polymorphisms within the interferon lambda (IFN-lambda) chromosomal region, mainly rs12979860 of IFN-lambda4 gene (IFNL4), are known as associated with spontaneous hepatitis C virus (HCV) resolution and sustained viral response to therapy with pegylated interferon- alpha and ribavirin. Ribavirin 284-293 interferon lambda 4 (gene/pseudogene) Homo sapiens 123-128 27027531-0 2017 IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. AIM: Older patients with chronic hepatitis C have a lower virological response to interferon (IFN)-based treatments compared to younger patients. Ribavirin 72-81 interferon lambda 4 (gene/pseudogene) Homo sapiens 0-5 27735085-0 2017 Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-alpha and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C. BACKGROUND: The aim of this study was to determine whether two polymorphisms of the human interferon lambda 4 (IFNL4) gene (rs12979860 and rs8099917) can predict sustained virologic response (SVR) following antiviral therapy in patients with inherited bleeding disorder and chronic hepatitis C (CHC). Ribavirin 95-104 interferon lambda 4 (gene/pseudogene) Homo sapiens 10-15 27735085-8 2017 CONCLUSION: These results demonstrate that polymorphisms of the IFNL4 gene are highly associated with SVR to PegIFN and RBV combination therapy in patients with a congenital bleeding disorder and CHC. Ribavirin 120-123 interferon lambda 4 (gene/pseudogene) Homo sapiens 64-69 27904617-0 2016 The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. BACKGROUND: A dinucleotide variant rs368234815 in interferon lambda 4 (IFNL4) gene was recently found to be associated with the hepatitis C virus (HCV) treatment response. Ribavirin 98-107 interferon lambda 4 (gene/pseudogene) Homo sapiens 4-23 27904617-0 2016 The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. BACKGROUND: A dinucleotide variant rs368234815 in interferon lambda 4 (IFNL4) gene was recently found to be associated with the hepatitis C virus (HCV) treatment response. Ribavirin 98-107 interferon lambda 4 (gene/pseudogene) Homo sapiens 207-226 27904617-0 2016 The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C. BACKGROUND: A dinucleotide variant rs368234815 in interferon lambda 4 (IFNL4) gene was recently found to be associated with the hepatitis C virus (HCV) treatment response. Ribavirin 98-107 interferon lambda 4 (gene/pseudogene) Homo sapiens 228-233 27904617-1 2016 This study aimed to assess the impact of IFNL4 rs368234815 polymorphism on treatment response to pegylated-IFN alpha (Peg-IFN-alpha) and ribavirin (RBV) in hemophilic patients with chronic hepatitis C (CHC). Ribavirin 137-146 interferon lambda 4 (gene/pseudogene) Homo sapiens 41-46 27904617-1 2016 This study aimed to assess the impact of IFNL4 rs368234815 polymorphism on treatment response to pegylated-IFN alpha (Peg-IFN-alpha) and ribavirin (RBV) in hemophilic patients with chronic hepatitis C (CHC). Ribavirin 148-151 interferon lambda 4 (gene/pseudogene) Homo sapiens 41-46 24362944-0 2014 Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. BACKGROUND: Older patients with chronic hepatitis C have a lower virological response to interferon (IFN) treatment compared to younger patients. Ribavirin 88-97 interferon lambda 4 (gene/pseudogene) Homo sapiens 24-29 26186989-3 2015 METHODS: We compared IFNL4-DeltaG/TT and rs4803217 for association with response to pegylated-IFN-alpha/ribavirin in the VIRAHEP-C and HALT-C trials, and spontaneous HCV clearance in the ALIVE, UHS and WIHS studies. Ribavirin 104-113 interferon lambda 4 (gene/pseudogene) Homo sapiens 21-26 26032235-1 2015 BACKGROUND: The biological mechanism underlying the association between IFNL4/IFNL3 polymorphism and peginterferon/ribavirin (PR) response in HCV-1 is thought to involve differential intrahepatic interferon-stimulated gene expression. Ribavirin 115-124 interferon lambda 4 (gene/pseudogene) Homo sapiens 72-77 27180197-0 2016 Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis. Ribavirin 150-159 interferon lambda 4 (gene/pseudogene) Homo sapiens 20-25 27180197-1 2016 BACKGROUND AND AIMS: Many studies have been published on the association between IFNL4 rs368234815 single-nucleotide polymorphism (SNP) and sustained virological response (SVR) in chronic hepatitis C (CHC) patients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV). Ribavirin 277-286 interferon lambda 4 (gene/pseudogene) Homo sapiens 81-86 27180197-1 2016 BACKGROUND AND AIMS: Many studies have been published on the association between IFNL4 rs368234815 single-nucleotide polymorphism (SNP) and sustained virological response (SVR) in chronic hepatitis C (CHC) patients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV). Ribavirin 288-291 interferon lambda 4 (gene/pseudogene) Homo sapiens 81-86 24415789-1 2014 BACKGROUND: The polymorphisms of IFNL4 are strongly associated with both spontaneous hepatitis C virus (HCV) clearance and response to peg-IFN-alpha/ribavirin treatment. Ribavirin 149-158 interferon lambda 4 (gene/pseudogene) Homo sapiens 33-38 24367041-0 2014 IFNL4-DeltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. Ribavirin 128-137 interferon lambda 4 (gene/pseudogene) Homo sapiens 0-5 24367041-3 2014 We report that in patients treated with the DAA sofosbuvir along with RBV, IFNL4-DeltaG is associated with slower early viral decay, due to slower loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevance of IFN-lambda4 in IFN-alpha-free DAA therapies. Ribavirin 70-73 interferon lambda 4 (gene/pseudogene) Homo sapiens 75-80 24495847-0 2014 Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 DeltaG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients. Ribavirin 193-202 interferon lambda 4 (gene/pseudogene) Homo sapiens 48-53 24205831-0 2014 Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. BACKGROUND: The IL28B genotype in rs12979860 predicts success of peginterferon/ribavirin (PEG/RBV) therapy in patients with chronic hepatitis C (CHC). Ribavirin 92-101 interferon lambda 4 (gene/pseudogene) Homo sapiens 17-35 25548683-11 2014 IFNL4 ss469415590 variant and HCV viral loads or IFNL4 ss469415590 variant and early virological response were better predictors of SVR in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. Ribavirin 174-183 interferon lambda 4 (gene/pseudogene) Homo sapiens 0-5 25548683-11 2014 IFNL4 ss469415590 variant and HCV viral loads or IFNL4 ss469415590 variant and early virological response were better predictors of SVR in patients treated with peg-IFN plus ribavirin with or without telaprevir, respectively. Ribavirin 174-183 interferon lambda 4 (gene/pseudogene) Homo sapiens 49-54 24355007-0 2014 Genetic polymorphism in IFNL4 and response to pegylated interferon-alpha and ribavirin in Japanese chronic hepatitis C patients. Ribavirin 77-86 interferon lambda 4 (gene/pseudogene) Homo sapiens 24-29 23939236-2 2013 Analysing 206 HCV(+)/HIV(+) and 162 HCV(+)/HIV(-) patients, we found that compared with IL28B rs12979860, IFNL4 ss469415590 was strongly associated with response to interferon/ribavirin therapy in HCV(+)/HIV(-) individuals but not in HIV(+)/HCV(+) patients. Ribavirin 176-185 interferon lambda 4 (gene/pseudogene) Homo sapiens 106-111